
CervoMed Inc (CRVO) Stock Forecast & Price Target
CervoMed Inc (CRVO) Analyst Ratings
Bulls say
CervoMed is a clinical biotechnology company that is developing a potential treatment for age-related neurologic disorders called Neflamapimod. They have a strong pipeline and have recently secured funding for a pivotal clinical trial for ALS and strengthened their balance sheet through a private placement and equity offering. The completion of their mid-stage trial is expected to yield positive results, and their product revenue is expected to increase in the future.
Bears say
CervoMed is a clinical-stage biotechnology company that is still in the early phases of development and has yet to generate significant revenue. The analysis of neflamapimod's treatment potential in neurodegenerative diseases, including dementia with Lewy bodies and frontotemporal dementia, is promising but still needs to undergo further clinical trials. Despite the potential of their product candidate, CervoMed's financials show low revenue and high operating expenses, making their stock unattractive to investors.
This aggregate rating is based on analysts' research of CervoMed Inc and is not a guaranteed prediction by Public.com or investment advice.
CervoMed Inc (CRVO) Analyst Forecast & Price Prediction
Start investing in CervoMed Inc (CRVO)
Order type
Buy in
Order amount
Est. shares
0 shares